Form 4: GeneDx Holdings Corp. CEO Katherine Stueland Reports Stock Transactions
SEC Form 4 Filing
Katherine Stueland, CEO of GeneDx Holdings Corp., reports the acquisition of 6,547 shares of Class A Common Stock and corresponding disposal of restricted stock units on March 9, 2024.
Summary
- On March 9, 2024, Katherine Stueland, the CEO of GeneDx Holdings Corp., acquired 6,547 shares of Class A Common Stock.
- This acquisition was related to the vesting of restricted stock units.
- Ms. Stueland also disposed of 6,547 restricted stock units.
- Following these transactions, Ms. Stueland directly owns 59,125 shares of Class A Common Stock and 72,011 restricted stock units.
- The restricted stock units vest in quarterly installments over a 4-year period starting March 9, 2023.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, and carries a neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.
Stakeholder Impact
- The filing provides transparency to shareholders regarding executive stock ownership.
- The vesting of restricted stock units aligns executive interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/09/2023 | Commencement date for quarterly vesting of restricted stock units over a 4-year period. |
| 03/09/2024 | Date of transaction: Acquisition of Class A Common Stock and disposal of restricted stock units. |
| 03/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.